MASIMO CORP (MASI) rated Buy with price target $28 by Collins Stewart
Collins Stewart rated Buy MASIMO CORP (NASDAQ: MASI) on 09/14/2011, when the stock price was $23.08. Since
then, MASIMO CORP has gained 6.11% as of 12/17/2014's recent price of $24.49. If you would have followed this Collins Stewart's recommendation on MASI, you would have gained 6.1% of your investment in 1190 days.
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve `unsolvable` problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of `Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.`
's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Quest™ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart
cornerstone; it is leveraged throughout the organisation.